Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
700 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015', provides an overview of the Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 19 Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 21 Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 25 Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 38 Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 40 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 132 Drug Profiles 152 Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 456 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 656 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 666 Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 669 Appendix 681
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2015 27 Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2015 28 Number of Products under Development by Companies, H2 2015 30 Number of Products under Development by Companies, H2 2015 (Contd..1) 31 Number of Products under Development by Companies, H2 2015 (Contd..2) 32 Number of Products under Development by Companies, H2 2015 (Contd..3) 33 Number of Products under Development by Companies, H2 2015 (Contd..4) 34 Number of Products under Development by Companies, H2 2015 (Contd..5) 35 Number of Products under Development by Companies, H2 2015 (Contd..6) 36 Number of Products under Investigation by Universities/Institutes, H2 2015 38 Comparative Analysis by Late Stage Development, H2 2015 39 Comparative Analysis by Clinical Stage Development, H2 2015 40 Comparative Analysis by Early Stage Development, H2 2015 41 Comparative Analysis by Unknown Stage Development, H2 2015 42 Products under Development by Companies, H2 2015 43 Products under Development by Companies, H2 2015 (Contd..1) 44 Products under Development by Companies, H2 2015 (Contd..2) 45 Products under Development by Companies, H2 2015 (Contd..3) 46 Products under Development by Companies, H2 2015 (Contd..4) 47 Products under Development by Companies, H2 2015 (Contd..5) 48 Products under Development by Companies, H2 2015 (Contd..6) 49 Products under Development by Companies, H2 2015 (Contd..7) 50 Products under Development by Companies, H2 2015 (Contd..8) 51 Products under Development by Companies, H2 2015 (Contd..9) 52 Products under Development by Companies, H2 2015 (Contd..10) 53 Products under Development by Companies, H2 2015 (Contd..11) 54 Products under Development by Companies, H2 2015 (Contd..12) 55 Products under Investigation by Universities/Institutes, H2 2015 56 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 57 Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2015 58 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2015 59 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 60 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H2 2015 61 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H2 2015 62 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprogen, Inc., H2 2015 63 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2015 64 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2015 65 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 66 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2015 67 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2015 68 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 69 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 70 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen, Inc., H2 2015 71 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioInvent International AB, H2 2015 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H2 2015 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera, Inc., H2 2015 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2015 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2015 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H2 2015 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences, Inc., H2 2015 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by CTI BioPharma Corp., H2 2015 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H2 2015 83 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H2 2015 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H2 2015 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co., Ltd., H2 2015 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2015 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hospira, Inc., H2 2015 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2015 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H2 2015 93 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H2 2015 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2015 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2015 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2015 97 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Limited, H2 2015 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2015 100 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H2 2015 101 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2015 102 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2015 103 Chronic Lymphocytic Leukemia (CLL) - Pipeline by KAEL-GemVax Co., Ltd., H2 2015 104 Chronic Lymphocytic Leukemia (CLL) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015 105 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2015 106 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 107 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H2 2015 108 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H2 2015 109 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2015 110 Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2015 111 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015 112 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc, H2 2015 113 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MediGene AG, H2 2015 114 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2015 115 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H2 2015 116 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H2 2015 117 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2015 118 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 119 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H2 2015 120 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Molecular Templates Inc., H2 2015 121 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2015 122 Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest, Inc., H2 2015 123 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2015 124 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 125 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 126 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H2 2015 127 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H2 2015 128 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H2 2015 129 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 130 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H2 2015 131 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2015 132 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H2 2015 133 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2015 134 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H2 2015 135 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015 136 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H2 2015 137 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics, Inc., H2 2015 138 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H2 2015 139 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme, Inc., H2 2015 140 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2015 141 Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 142 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H2 2015 143 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 144 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 145 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015 146 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ViDAC Pharma Ltd., H2 2015 147 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H2 2015 148 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc., H2 2015 149 Assessment by Monotherapy Products, H2 2015 150 Assessment by Combination Products, H2 2015 151 Number of Products by Stage and Target, H2 2015 153 Number of Products by Stage and Mechanism of Action, H2 2015 161 Number of Products by Stage and Route of Administration, H2 2015 167 Number of Products by Stage and Molecule Type, H2 2015 169 Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2015 474 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2015 674 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2015 675 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H2 2015 676 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H2 2015 677 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H2 2015 678 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H2 2015 679 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H2 2015 680 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H2 2015 681 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H2 2015 682 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H2 2015 683 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2015 684 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H2 2015 685 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..2), H2 2015 686
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
